Table 2.
GS upgrade and disease upstage rates of the groups
| Parameters | NLR 2.5 (n=104) | NLR ≥2.5 (n=106) | p value | NC <4.2 × 1019/L (n=103) | NC ≥4.2 × 1019/L (n=107) | p value | LC <1.4 × 1019/L (n=106) | LC ≥1.4 × 1019/L (n=104) | p value |
|---|---|---|---|---|---|---|---|---|---|
| GS upgrade, n (%) | 0.04 | 0.25 | 0.59 | ||||||
| Yes | 27 (25.9) | 42 (39.6) | 30 (29.1) | 39 (36.4) | 33 (31.1) | 36 (34.6) | |||
| No | 77 (74.1) | 64 (60.4) | 73 (70.9) | 68 (63.6) | 73 (68.9) | 68 (65.4) | |||
| GS distribution | 0.03 | 0.28 | 0.85 | ||||||
| GS 6 | 77 (74.1) | 64 (60.4) | 73 (70.9) | 68 (63.6) | 73 (68.9) | 68 (65.4) | |||
| GS 7 | 26 (25.0) | 35 (33.0) | 28 (27.2) | 33 (30.8) | 29 (27.4) | 32 (30.8) | |||
| GS 8–10 | 1 (0.9) | 7 (6.6) | 2 (1.9) | 6 (5.6) | 4 (3.7) | 4 (3.8) | |||
| Disease upstaging | 0.20 | 0.59 | 0.12 | ||||||
| Yes | 9 (8.6) | 16 (15.1) | 11 (10.7) | 14 (13.1) | 9 (8.5) | 16 (15.4) | |||
| No | 95 (91.4) | 90 (84.9) | 92 (89.3) | 93 (86.9) | 97 (91.5) | 88 (84.6) |
GS: Gleason score; LC: lymphocyte count; NC: neutrophil count; NLR: neutrophil-to-lymphocyte ratio.